Organisation: Sanofi

Biosimilars and biologics litigation in the United States

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

Whether the new Inflation Reduction Act will protect and foster the growing biosimilar market remains to be seen, but litigation in the biosimilars space has already transformed the landscape, making it increasingly difficult to navigate for biopharma companies and IP professionals.

25 August 2023

What AI means for the life sciences space

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

Considered as a significant boost to the life sciences space, AI and machine learning are being increasingly integrated into many scientific fields, helping companies to provide faster, cheaper solutions with a wider public reach, and contributing to IP rights portfolio creation and management.

25 August 2023

Data shows New Jersey district court’s key for biopharma patent litigation

We have scoured Docket Navigator for must-know metrics on case filing trends, rulings on important motions, injunctive relief and damages awards

12 December 2022